
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16197441
[patent_doc_number] => 10722578
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-28
[patent_title] => Methods and compositions for treating neuroblastoma
[patent_app_type] => utility
[patent_app_number] => 14/607573
[patent_app_country] => US
[patent_app_date] => 2015-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 69
[patent_no_of_words] => 25653
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14607573
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/607573 | Methods and compositions for treating neuroblastoma | Jan 27, 2015 | Issued |
Array
(
[id] => 10312574
[patent_doc_number] => 20150197576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-16
[patent_title] => 'Identification of Tumor-Associated Antigens for Diagnosis and Therapy'
[patent_app_type] => utility
[patent_app_number] => 14/606729
[patent_app_country] => US
[patent_app_date] => 2015-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 46
[patent_figures_cnt] => 46
[patent_no_of_words] => 23458
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14606729
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/606729 | Identification of tumor-associated antigens for diagnosis and therapy | Jan 26, 2015 | Issued |
Array
(
[id] => 10327072
[patent_doc_number] => 20150212077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-30
[patent_title] => 'BIOMARKER TFF1 FOR PREDICTING EFFECT OF C-MET INHIBITOR'
[patent_app_type] => utility
[patent_app_number] => 14/604361
[patent_app_country] => US
[patent_app_date] => 2015-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 23328
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14604361
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/604361 | Biomarker TFF1 for predicting effect of C-MET inhibitor | Jan 22, 2015 | Issued |
Array
(
[id] => 10233249
[patent_doc_number] => 20150118243
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-04-30
[patent_title] => 'Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma'
[patent_app_type] => utility
[patent_app_number] => 14/597786
[patent_app_country] => US
[patent_app_date] => 2015-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 26
[patent_no_of_words] => 18860
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14597786
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/597786 | Methods and compositions for identifying, diagnosing, and treating neuroblastoma | Jan 14, 2015 | Issued |
Array
(
[id] => 11290475
[patent_doc_number] => 20160340407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-24
[patent_title] => 'COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS'
[patent_app_type] => utility
[patent_app_number] => 15/110808
[patent_app_country] => US
[patent_app_date] => 2015-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 64303
[patent_no_of_claims] => 87
[patent_no_of_ind_claims] => 43
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110808
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/110808 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS | Jan 13, 2015 | Abandoned |
Array
(
[id] => 10408091
[patent_doc_number] => 20150293101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-10-15
[patent_title] => 'TUMOR CELL-DERIVED MICROVESICLES'
[patent_app_type] => utility
[patent_app_number] => 14/595148
[patent_app_country] => US
[patent_app_date] => 2015-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 14619
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14595148
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/595148 | Tumor cell-derived microvesicles | Jan 11, 2015 | Issued |
Array
(
[id] => 11562881
[patent_doc_number] => 09625461
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-04-18
[patent_title] => 'Method of detecting cancer using delta-catenin'
[patent_app_type] => utility
[patent_app_number] => 14/592499
[patent_app_country] => US
[patent_app_date] => 2015-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 10230
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592499
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/592499 | Method of detecting cancer using delta-catenin | Jan 7, 2015 | Issued |
Array
(
[id] => 11798622
[patent_doc_number] => 09539340
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-01-10
[patent_title] => 'Bladder cancer specific ligand peptides'
[patent_app_type] => utility
[patent_app_number] => 14/589680
[patent_app_country] => US
[patent_app_date] => 2015-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 31
[patent_no_of_words] => 23403
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14589680
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/589680 | Bladder cancer specific ligand peptides | Jan 4, 2015 | Issued |
Array
(
[id] => 13117943
[patent_doc_number] => 10077316
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-18
[patent_title] => Esophageal cancer marker and use thereof
[patent_app_type] => utility
[patent_app_number] => 15/108251
[patent_app_country] => US
[patent_app_date] => 2014-12-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 40
[patent_no_of_words] => 48123
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15108251
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/108251 | Esophageal cancer marker and use thereof | Dec 24, 2014 | Issued |
Array
(
[id] => 11129623
[patent_doc_number] => 20160326597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-11-10
[patent_title] => 'DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY'
[patent_app_type] => utility
[patent_app_number] => 15/109464
[patent_app_country] => US
[patent_app_date] => 2014-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 75
[patent_figures_cnt] => 75
[patent_no_of_words] => 25597
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15109464
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/109464 | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY | Dec 22, 2014 | Abandoned |
Array
(
[id] => 10346216
[patent_doc_number] => 20150231221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-08-20
[patent_title] => 'IMMUNOGENIC COMPOSITIONS COMPRISING PROGASTRIN AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/579220
[patent_app_country] => US
[patent_app_date] => 2014-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 11572
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579220
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/579220 | Immunogenic compositions comprising progastrin and uses thereof | Dec 21, 2014 | Issued |
Array
(
[id] => 12029562
[patent_doc_number] => 20170319661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-09
[patent_title] => 'Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers'
[patent_app_type] => utility
[patent_app_number] => 15/531128
[patent_app_country] => US
[patent_app_date] => 2014-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 12595
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15531128
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/531128 | Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers | Dec 2, 2014 | Abandoned |
Array
(
[id] => 10268351
[patent_doc_number] => 20150153347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-06-04
[patent_title] => 'LUNG CANCER DIAGNOSTIC ASSAY'
[patent_app_type] => utility
[patent_app_number] => 14/552534
[patent_app_country] => US
[patent_app_date] => 2014-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20830
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14552534
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/552534 | LUNG CANCER DIAGNOSTIC ASSAY | Nov 24, 2014 | Abandoned |
Array
(
[id] => 11310197
[patent_doc_number] => 20160346307
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-12-01
[patent_title] => 'ANTICANCER ADJUVANT COMPOSITION CONTAINING RIP3 EXPRESSION PROMOTER AS ACTIVE INGREDIENT, METHOD FOR SCREENING FOR ANTICANCER ADJUVANT ENHANCING SENSITIVITY OF ANTICANCER DRUG BY PROMOTING RIP3 EXPRESSION, AND METHOD FOR MONITORING SENSITIVITY OF ANTICANCER DRUG'
[patent_app_type] => utility
[patent_app_number] => 15/116591
[patent_app_country] => US
[patent_app_date] => 2014-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 6396
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15116591
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/116591 | Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug | Nov 24, 2014 | Issued |
Array
(
[id] => 15247033
[patent_doc_number] => 10509034
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-17
[patent_title] => Bladder carcinoma biomarkers
[patent_app_type] => utility
[patent_app_number] => 15/034585
[patent_app_country] => US
[patent_app_date] => 2014-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 14
[patent_no_of_words] => 14449
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15034585
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/034585 | Bladder carcinoma biomarkers | Nov 4, 2014 | Issued |
Array
(
[id] => 11074275
[patent_doc_number] => 20160271239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-22
[patent_title] => 'Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor'
[patent_app_type] => utility
[patent_app_number] => 15/034496
[patent_app_country] => US
[patent_app_date] => 2014-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 18756
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15034496
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/034496 | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor | Oct 30, 2014 | Abandoned |
Array
(
[id] => 10381964
[patent_doc_number] => 20150266971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-09-24
[patent_title] => 'MN/CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED FROM MN/CA IX-DEFICIENT MICE AND METHODS OF USE'
[patent_app_type] => utility
[patent_app_number] => 14/529138
[patent_app_country] => US
[patent_app_date] => 2014-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 46103
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14529138
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/529138 | MN/CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED FROM MN/CA IX-DEFICIENT MICE AND METHODS OF USE | Oct 29, 2014 | Abandoned |
Array
(
[id] => 11874713
[patent_doc_number] => 09746480
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-08-29
[patent_title] => 'Human myeloid derived suppressor cell cancer markers'
[patent_app_type] => utility
[patent_app_number] => 14/520158
[patent_app_country] => US
[patent_app_date] => 2014-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 13
[patent_no_of_words] => 18901
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14520158
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/520158 | Human myeloid derived suppressor cell cancer markers | Oct 20, 2014 | Issued |
Array
(
[id] => 14029571
[patent_doc_number] => 10226518
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-12
[patent_title] => Ubiquitinylated proteins
[patent_app_type] => utility
[patent_app_number] => 14/512322
[patent_app_country] => US
[patent_app_date] => 2014-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 20
[patent_no_of_words] => 5695
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14512322
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/512322 | Ubiquitinylated proteins | Oct 9, 2014 | Issued |
Array
(
[id] => 11102173
[patent_doc_number] => 20160299143
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-10-13
[patent_title] => 'BREAST CANCER DIAGNOSTIC METHOD AND MEANS'
[patent_app_type] => utility
[patent_app_number] => 15/026951
[patent_app_country] => US
[patent_app_date] => 2014-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 14912
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15026951
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/026951 | BREAST CANCER DIAGNOSTIC METHOD AND MEANS | Sep 30, 2014 | Abandoned |